INCI · — · CIR review pending · used in 16 products
팔미토일트라이펩타이드-1
PALMITOYL TRIPEPTIDE-1
Evidence level
moderateEWG score
—Comedogenic
—Category
—● Benefits
Benefits to be documented.
● Cautions
No known cautions documented in the catalog.
Benefits to be documented.
No known cautions documented in the catalog.